ANNEX附則
ANNEX The Annexes to Directive 2004/37/EC are amended as follows: (1) in Annex III, point A is amended as follows: (a) the row related to benzene is replaced by the following: Name of agent EC No ( 1 ) CAS No ( 2 ) Limit values Notation Transitional measures 8 hours ( 3 ) Short-term ( 4 ) mg/m 3 ( 5 ) ppm ( 6 ) f/ml ( 7 ) mg/m 3 ppm f/ml ‘Benzene 200-753-7 71-43-2 0,66 0,2 – – – – Skin ( 8 ) Limit value 1 ppm (3,25 mg/m 3 ) until 5 April 2024. Limit value 0,5 ppm (1,65 mg/m 3 ) from 5 April 2024 until 5 April 2026.’ (b) the following rows are added: Name of agent EC No ( 1 ) CAS No ( 2 ) Limit values Notation Transitional measures 8 hours ( 3 ) Short-term ( 4 ) mg/m 3 ( 5 ) ppm ( 6 ) f/ml ( 7 ) mg/m 3 ppm f/ml ‘Acrylonitrile 203-466-5 107-13-1 1 0,45 – 4 1,8 – Skin ( 8 ) Dermal sensitisation ( 9 ) The limit values shall apply from 5 April 2026. Nickel compounds – – 0,01 ( 10 ) 0,05 ( 11 ) – – – – – Dermal and respiratory sensitisation ( 12 ) The limit value ( 10 ) shall apply from 18 January 2025 The limit value ( 11 ) shall apply from 18 January 2025. Until then a limit value of 0,1 mg/m 3 ( 11 ) shall apply. Inorganic lead and its compounds 0,15 N,N-Dimethylacetamide 204-826-4 127-19-5 36 10 72 20 Skin ( 8 ) Nitrobenzene 202-716-0 98-95-3 1 0,2 Skin ( 8 ) N,N Dimethylformamide 200-679-5 68-12-2 15 5 30 10 Skin ( 8 ) 2-Methoxyethanol 203-713-7 109-86-4 1 Skin ( 8 ) 2-Methyoxyethyl acetate 203-772-9 110-49-6 1 Skin ( 8 ) 2-Ethoxy ethanol 203-804-1 110-80-5 8 2 Skin ( 8 ) 2-Ethoxyethyl acetate 203-839-2 111-15-9 11 2 Skin ( 8 ) 1-Methyl-2-pyrrolidone 212-828-1 872-50-4 40 10 80 20 Skin ( 8 ) Mercury and divalent inorganic mercury compounds including mercuric oxide and mercuric chloride (measured as mercury) 0,02 Bisphenol A; 4,4′-Isopropylidenediphenol 201-245-8 80-05-7 2 ( 13 ) Carbon monoxide 211-128-3 630-08-0 23 20 117 100 (2) the following annex is inserted: ‘ANNEX IIIa BIOLOGICAL LIMIT VALUES AND HEALTH SURVEILLANCE MEASURES (Article 16(4)) 1. Lead and its ionic compounds 1.1. Biological monitoring must include measuring the blood-lead level (PbB) using absorption spectrometry or a method giving equivalent results. The binding biological limit value is: 70 μg Pb/100 ml blood 1.2. Medical surveillance is carried out if exposure to a concentration of lead in air is greater than 0,075 mg/m 3 , calculated as a time-weighted average over 40 hours per week, or a blood-lead level greater than 40 μg Pb/100 ml blood is measured in individual workers. ’. ( 1 ) EC No, i.e. Einecs, ELINCS or NLP, is the official number of the substance within the European Union, as defined in Section 1.1.1.2 in Annex VI, Part 1, to Regulation (EC) No 1272/2008. ( 2 ) CAS No: Chemical Abstract Service Registry Number. ( 3 ) Measured or calculated in relation to a reference period of eight hours time-weighted average (TWA). ( 4 ) Short-term exposure limit (STEL). A limit value above which exposure should not occur and which is related to a 15-minute period unless otherwise specified. ( 5 ) mg/m 3 = milligrams per cubic metre of air at 20 °C and 101,3 kPa (760 mm mercury pressure). ( 6 ) ppm = parts per million by volume in air (ml/m 3 ). ( 7 ) f/ml = fibres per millilitre. ( 8 ) Substantial contribution to the total body burden via dermal exposure possible. ( 9 ) The substance can cause sensitisation of the skin. ( 10 ) Respirable fraction, measured as nickel. ( 11 ) Inhalable fraction, measured as nickel. ( 12 ) The substance can cause sensitisation of the skin and of the respiratory tract. ( 13 ) Inhalable fraction.’;